Drug Trial Radar · NCT04680026
A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)
Last checked: Nov 20, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jun 1, 2021
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- HUYABIO International, LLC.Industry
- Sponsor type
- Industry
- First posted
- Dec 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 study is a two-stage, serial cohort dose escalation and expansion study of a single 30-minute (IV) infusion of HBI-3000 for the conversion of patients with recent-onset atrial fibrillation (AF). Stage A is open label and all patients will receive HBI-3000. In each of three dose cohorts, up to 10 patients will receive HBI-3000 by IV infusion (30 minutes). Three different dose levels are planned to be administered serially, lowest to highest, with assessment of safety, tolerability, and efficacy prior to proceeding to the next dose level group. Following Stage A, the iDMC will recommend up to two doses of HBI-3000 to be further explored in Stage B. Stage B is a serial, randomized, double-blind and placebo-controlled cohort of two different doses of HBI-3000, with a dose decision after the first cohort. Stage B will be powered to show a difference between HBI-3000 and placebo in conversion rate at each of the two dose levels.
Conditions
- Atrial Fibrillation
Interventions
HBI-3000Drug
Small molecule, multi-ion channel blocker
PlaceboDrug
Normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety of intravenously (IV) administered HBI-3000 in patients with Atrial Fibrillation (AF) of recent onset, as measured by the incidence of adverse events (AEs)Time frame: 30 days
- Evaluate the safety of intravenously (IV) administered HBI-3000 in patients with Atrial Fibrillation (AF) of recent onset, as measured by changes in heart rate (HR)Time frame: 90 minutes
- Evaluate the safety of intravenously (IV) administered HBI-3000 in patients with Atrial Fibrillation (AF) of recent onset, as measured by change in blood pressure (BP)Time frame: 90 minutes
- Evaluate the safety of intravenously (IV) administered HBI-3000 in patients with Atrial Fibrillation (AF) of recent onset, as measured by ECG interval changes above a specific levelTime frame: 24 hours
- The efficacy of intravenously (IV) administered HBI-3000 as measured by the proportion of patients with AF of recent onset who convert to SRTime frame: 120 minutes
Locations
14 sites in 5 countries. Site status is shown where the registry gives one.
NCH Research Institute
Naples, Florida
Prairie Education & Research
Springfield, Illinois
North Mississippi Medical Center
Tupelo, Mississippi
CHRISTUS Trinity Mother Frances Hospital - Tyler
Tyler, Texas
University Clinical Center of the Republic of Srpska
Banja Luka, Bosnia and Herzegovina
Montreal Heart Institute
Montreal, Quebec, Canada
Centre hospitalier de L'Universite de Montral (CHUM)
Montreal, Quebec, Canada
Centre integre de sante et de services sociaux de Lanaudiere - Hopital Pierre-Le Gardeur
Terrebonne, Quebec, Canada
Waikato Hospital
Hamilton, New Zealand
Wellington Regional Hospital
Wellington, New Zealand
University Clinical Center of Serbia
Belgrade, Serbia
Dedinje Institute for Cardiovascular Diseases
Belgrade, Serbia
University Hospital Medical Center Bezanijska kosa
Belgrade, Serbia
Niš University Clinical Center
Niš, Bulevar Doktora, Serbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.